Iqirvo
Payments companies reported to CMS as associated with Iqirvo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Iqirvo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Iqirvo
These are the largest totals companies reported as associated with Iqirvo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Pierre Gholam | Cleveland, OH | Gastroenterology (Internal Medicine) | $152,398.19 |
| Sonal Kumar | New York, NY | Gastroenterology (Internal Medicine) | $134,684.88 |
| Steven Flamm | Chicago, IL | Gastroenterology (Internal Medicine) | $118,013.35 |
| Hany Elbeshbeshy | Saint Louis, MO | Hepatology | $105,076.77 |
| Robert Gish | Folsom, CA | Hepatology | $98,079.39 |
| Lance Stein | Atlanta, GA | Transplant Hepatology | $88,449.77 |
| Naim Alkhouri | Westlake, OH | Gastroenterology (Internal Medicine) | $79,162.79 |
| Nadege Gunn | Waco, TX | Gastroenterology (Internal Medicine) | $71,548.05 |
| Sammy Saab | Los Angeles, CA | Gastroenterology (Internal Medicine) | $69,102.70 |
| Ayman Koteish | Orlando, FL | Transplant Hepatology | $68,545.17 |
Prescribed Iqirvo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.